Resonance Specialties Ltd. – Company Report
1. Company Overview
Resonance Specialties Ltd., established in 1989 and headquartered in Mumbai, Maharashtra, is one of India’s early entrants in the manufacturing of pyridine and its derivatives. These chemical compounds are used across various industries, including pharmaceuticals, agrochemicals, nutraceuticals, dyes, and specialty chemicals. The company operates four integrated manufacturing units and is known for being the first Indian manufacturer of several pyridine-based products. Resonance emphasizes backward integration, process innovation, and global outreach, serving a diverse clientele in India and overseas.
Incorporated: 1989 (formerly Armour Polymers)
Headquarters: Mumbai, Maharashtra
Employees: 100–500
Manufacturing: Four fully integrated units
Certifications: ISO 9001
Listed on: NSE, BSE
Leadership:
- Archana Surendra Yadav – Chairperson
- Gaurav Vijay Dalal – CMD
- Prashant Godha – Director
- Charchit Jain – CFO
Market Cap (Aug 2025): ~₹135 crore
Strengths: First-mover in pyridine chemistry, strong export orientation, technology-driven operations, near debt-free balance sheet
2. Products and Services
- Pyridine & Derivatives – Used in pharmaceuticals (e.g., anti-tuberculosis, anti-ulcer drugs), agrochemicals, vitamins, and dyes
- Picolines (Alpha, Beta, Gamma) – For rubber chemicals, vitamins, and pharma applications
- Lutidines & Collidines – Used in specialty and bulk drug synthesis
- Nutritional APIs – Zinc picolinate, chromium picolinate, niacin, etc.
- Catalyst Intermediates & Solvents – Acetonitrile, valeronitrile, and custom industrial molecules
- Custom/Captive R&D – In-house development of new intermediates and sustainable manufacturing processes
3. Recent News and Business Developments (2025)
- Recorded strong growth in both quarterly and annual profits, driven by operational efficiencies and export demand
- Expanded nutraceuticals portfolio and value-added intermediates for global markets
- Increased capacity utilization in FY2025 due to higher demand
- Declared 10% dividend for FY2025, highlighting financial stability
- Continued focus on R&D, product innovation, and compliance upgrades
4. Financial Performance (FY2025)
| Metric | FY2025 Value |
|---|---|
| Total Revenue | ₹78.79 crore |
| Net Profit | ₹6.57 crore |
| Operating Profit | ₹10.78 crore |
| Operating Profit Margin | 13.85% |
| Net Profit Margin | 8.5% |
| EPS | ₹5.69 |
| Dividend Payout % | 17.5% |
| Debt | Almost debt-free |